SpringWorks Therapeutics Analyst Ratings
SpringWorks Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 142.31% | HC Wainwright & Co. | $58 → $52 | Maintains | Buy |
| 11/09/2023 | 170.27% | HC Wainwright & Co. | $66 → $58 | Maintains | Buy |
| 08/24/2023 | 207.55% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
| 08/07/2023 | 207.55% | HC Wainwright & Co. | $105 → $66 | Maintains | Buy |
| 07/20/2023 | 128.33% | Goldman Sachs | $43 → $49 | Maintains | Buy |
| 06/06/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | Buy → Buy |
| 05/05/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
| 04/28/2023 | 91.05% | Barclays | $55 → $41 | Maintains | Overweight |
| 04/20/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
| 03/07/2023 | 165.61% | JP Morgan | $53 → $57 | Maintains | Overweight |
| 03/07/2023 | 389.28% | HC Wainwright & Co. | $99 → $105 | Maintains | Buy |
| 01/26/2023 | 109.69% | Goldman Sachs | $40 → $45 | Maintains | Buy |
| 12/01/2022 | 109.69% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 11/04/2022 | 361.32% | HC Wainwright & Co. | $103 → $99 | Maintains | Buy |
| 10/21/2022 | 105.03% | Goldman Sachs | $51 → $44 | Maintains | Buy |
| 09/12/2022 | 379.96% | HC Wainwright & Co. | $94 → $103 | Maintains | Buy |
| 08/09/2022 | 338.02% | HC Wainwright & Co. | $95 → $94 | Maintains | Buy |
| 06/06/2022 | 342.68% | HC Wainwright & Co. | $142 → $95 | Maintains | Buy |
| 05/27/2022 | 132.99% | Wedbush | $110 → $50 | Maintains | Outperform |
| 05/24/2022 | 282.11% | Goldman Sachs | $76 → $82 | Maintains | Buy |
| 09/08/2021 | 389.28% | JP Morgan | $97 → $105 | Maintains | Overweight |
| 08/05/2021 | 538.4% | HC Wainwright & Co. | $136 → $137 | Maintains | Buy |
| 07/21/2021 | 533.74% | HC Wainwright & Co. | $124 → $136 | Maintains | Buy |
| 03/22/2021 | 421.9% | Goldman Sachs | → $112 | Assumes | → Buy |
| 02/25/2021 | 477.82% | HC Wainwright & Co. | $101 → $124 | Maintains | Buy |
| 01/22/2021 | 328.7% | Barclays | $83 → $92 | Maintains | Overweight |
| 01/19/2021 | 370.64% | HC Wainwright & Co. | $87 → $101 | Maintains | Buy |
| 12/28/2020 | 305.41% | HC Wainwright & Co. | $73 → $87 | Reiterates | → Buy |
| 10/29/2020 | 240.17% | HC Wainwright & Co. | $58 → $73 | Maintains | Buy |
| 08/13/2020 | 132.99% | Wedbush | $48 → $50 | Maintains | Outperform |
| 05/13/2020 | 123.67% | Wedbush | $45 → $48 | Maintains | Outperform |
| 05/05/2020 | 123.67% | Barclays | → $48 | Initiates Coverage On | → Overweight |
| 04/14/2020 | 170.27% | HC Wainwright & Co. | $60 → $58 | Maintains | Buy |
| 03/19/2020 | 179.59% | HC Wainwright & Co. | $40 → $60 | Upgrades | Neutral → Buy |
| 03/04/2020 | 86.39% | HC Wainwright & Co. | → $40 | Downgrades | Buy → Neutral |
| 01/21/2020 | 86.39% | HC Wainwright & Co. | $34 → $40 | Maintains | Buy |
| 12/04/2019 | 53.77% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 10/08/2019 | 49.11% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/08/2019 | 53.77% | Wedbush | → $33 | Initiates Coverage On | → Outperform |
| 10/08/2019 | 72.41% | Goldman Sachs | → $37 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 142.31% | HC Wainwright & Co. | 58 美元 → 52 美元 | 維護 | 買 |
| 11/09/2023 | 170.27% | HC Wainwright & Co. | 66 美元 → 58 美元 | 維護 | 買 |
| 08/24/2023 | 207.55% | HC Wainwright & Co. | → 66 美元 | 重申 | 購買 → 購買 |
| 08/07/2023 | 207.55% | HC Wainwright & Co. | 105 美元 → 66 美元 | 維護 | 買 |
| 07/20/2023 | 128.33% | 高盛 | 43 美元 → 49 美元 | 維護 | 買 |
| 06/06/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | 購買 → 購買 |
| 05/05/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | → 購買 |
| 04/28/2023 | 91.05% | 巴克萊 | 55 美元 → 41 美元 | 維護 | 超重 |
| 04/20/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | → 購買 |
| 03/07/2023 | 165.61% | 摩根大通 | 53 美元 → 57 美元 | 維護 | 超重 |
| 03/07/2023 | 389.28% | HC Wainwright & Co. | 99 美元 → 105 美元 | 維護 | 買 |
| 01/26/2023 | 109.69% | 高盛 | 40 美元 → 45 美元 | 維護 | 買 |
| 2022 年 1 月 12 日 | 109.69% | B of A 類證券 | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 4 月 11 日 | 361.32% | HC Wainwright & Co. | 103 美元 → 99 美元 | 維護 | 買 |
| 10/21/2022 | 105.03% | 高盛 | 51 美元 → 44 美元 | 維護 | 買 |
| 09/12/2022 | 379.96% | HC Wainwright & Co. | 94 美元 → 103 美元 | 維護 | 買 |
| 08/09/2022 | 338.02% | HC Wainwright & Co. | 95 美元 → 94 美元 | 維護 | 買 |
| 2022 年 6 月 6 日 | 342.68% | HC Wainwright & Co. | 142 美元 → 95 美元 | 維護 | 買 |
| 05/27/2022 | 132.99% | Wedbush | 110 美元 → 50 美元 | 維護 | 跑贏大盤 |
| 2022 年 5 月 24 日 | 282.11% | 高盛 | 76 美元 → 82 美元 | 維護 | 買 |
| 09/08/2021 | 389.28% | 摩根大通 | 97 美元 → 105 美元 | 維護 | 超重 |
| 08/05/2021 | 538.4% | HC Wainwright & Co. | 136 美元 → 137 美元 | 維護 | 買 |
| 07/21/2021 | 533.74% | HC Wainwright & Co. | 124 美元 → 136 美元 | 維護 | 買 |
| 03/22/2021 | 421.9% | 高盛 | → 112 美元 | 假設 | → 購買 |
| 2021 年 2 月 25 日 | 477.82% | HC Wainwright & Co. | 101 美元 → 124 美元 | 維護 | 買 |
| 2021 年 1 月 22 日 | 328.7% | 巴克萊 | 83 美元 → 92 美元 | 維護 | 超重 |
| 01/19/2021 | 370.64% | HC Wainwright & Co. | 87 美元 → 101 美元 | 維護 | 買 |
| 12/28/2020 | 305.41% | HC Wainwright & Co. | 73 美元 → 87 美元 | 重申 | → 購買 |
| 10/29/2020 | 240.17% | HC Wainwright & Co. | 58 美元 → 73 美元 | 維護 | 買 |
| 08/13/2020 | 132.99% | Wedbush | 48 美元 → 50 美元 | 維護 | 跑贏大盤 |
| 05/13/2020 | 123.67% | Wedbush | 45 美元 → 48 美元 | 維護 | 跑贏大盤 |
| 05/05/2020 | 123.67% | 巴克萊 | → 48 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2020 年 4 月 14 日 | 170.27% | HC Wainwright & Co. | 60 美元 → 58 美元 | 維護 | 買 |
| 2020 年 3 月 19 日 | 179.59% | HC Wainwright & Co. | 40 美元 → 60 美元 | 升級 | 中性 → 買入 |
| 2020 年 4 月 3 日 | 86.39% | HC Wainwright & Co. | → 40 美元 | 降級 | 買入 → 中性 |
| 2020 年 1 月 21 日 | 86.39% | HC Wainwright & Co. | 34 美元 → 40 美元 | 維護 | 買 |
| 2019 年 4 月 12 日 | 53.77% | HC Wainwright & Co. | → 33 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 8 月 10 日 | 49.11% | 摩根大通 | → 32 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2019 年 8 月 10 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2019 年 8 月 10 日 | 53.77% | Wedbush | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2019 年 8 月 10 日 | 72.41% | 高盛 | → 37 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics（SWTX）的目標價格是多少？
The latest price target for SpringWorks Therapeutics (NASDAQ: SWTX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $52.00 expecting SWTX to rise to within 12 months (a possible 142.31% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月20日公佈了SpringWorks Therapeutics（納斯達克股票代碼：SWTX）的最新目標股價。該分析公司將目標股價定爲52.00美元，預計SWTX將在12個月內升至12個月內（可能上漲142.31％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics（SWTX）的最新分析師評級是多少？
The latest analyst rating for SpringWorks Therapeutics (NASDAQ: SWTX) was provided by HC Wainwright & Co., and SpringWorks Therapeutics maintained their buy rating.
SpringWorks Therapeutics（納斯達克股票代碼：SWTX）的最新分析師評級由HC Wainwright & Co. 提供，SpringWorks Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics（SWTX）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與SpringWorks Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。SpringWorks Therapeutics的最新評級是在2023年11月20日公佈的，因此你應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating SpringWorks Therapeutics (SWTX) correct?
分析師對SpringWorks Therapeutics（SWTX）的評級正確嗎？
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $58.00 to $52.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $21.46, which is out of the analyst's predicted range.
儘管評級是主觀的，而且會發生變化，但SpringWorks Therapeutics（SWTX）的最新評級維持不變，目標股價爲58.00美元至52.00美元。SpringWorks Therapeutics（SWTX）目前的交易價格爲21.46美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。